title: NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial).
abstract: BACKGROUND
  Surgical resection is the preferred treatment of potentially curable esophageal cancer. To improve long term patient outcome, many institutes apply neoadjuvant chemoradiotherapy. In a large proportion of patients no response to chemoradiotherapy is achieved. These patients suffer from toxic and ineffective neoadjuvant treatment, while appropriate surgical therapy is delayed. For this reason a diagnostic test that allows for accurate prediction of tumor response early during chemoradiotherapy is of crucial importance. CT-scan and endoscopic ultrasound have limited accuracy in predicting histopathologic tumor response. Data suggest that metabolic changes in tumor tissue as measured by FDG-PET predict response better. This study aims to compare FDG-PET and CT-scan for the early prediction of non-response to preoperative chemoradiotherapy in patients with potentially curable esophageal cancer.
  
  
  METHODS
  Prognostic accuracy study, embedded in a randomized multicenter Dutch trial comparing neoadjuvant chemoradiotherapy for 5 weeks followed by surgery versus surgery alone for esophageal cancer. This prognostic accuracy study is performed only in the neoadjuvant arm of the randomized trial. In 6 centers, 150 consecutive patients will be included over a 3 year period. FDG-PET and CT-scan will be performed before and 2 weeks after the start of the chemoradiotherapy. All patients complete the 5 weeks regimen of neoadjuvant chemoradiotherapy, regardless the test results. Pathological examination of the surgical resection specimen will be used as reference standard. Responders are defined as patients with < 10% viable residual tumor cells (Mandard-score).Difference in accuracy (area under ROC curve) and negative predictive value between FDG-PET and CT-scan are primary endpoints. Furthermore, an economic evaluation will be performed, comparing survival and costs associated with the use of FDG-PET (or CT-scan) to predict tumor response with survival and costs of neoadjuvant chemoradiotherapy without prediction of response (reference strategy).
  
  
  CONCLUSIONS
  The NEOPEC-trial could be the first sufficiently powered study that helps justify implementation of FDG-PET for response-monitoring in patients with esophageal cancer in clinical practice.
  
  
  BACKGROUND
  ISRCTN45750457.
authors.affiliation: Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands. m.vanheijl@amc.uva.nl
authors.forename: Mark
authors.initials: M
authors.lastname: van Heijl
authors.forename: Jikke M T
authors.initials: JM
authors.lastname: Omloo
authors.forename: Mark I
authors.initials: MI
authors.lastname: van Berge Henegouwen
authors.forename: Olivier R C
authors.initials: OR
authors.lastname: Busch
authors.forename: Hugo W
authors.initials: HW
authors.lastname: Tilanus
authors.forename: Patrick M M
authors.initials: PM
authors.lastname: Bossuyt
authors.forename: Otto S
authors.initials: OS
authors.lastname: Hoekstra
authors.forename: Jaap
authors.initials: J
authors.lastname: Stoker
authors.forename: Maarten C C M
authors.initials: MC
authors.lastname: Hulshof
authors.forename: Ate
authors.initials: A
authors.lastname: van der Gaast
authors.forename: Grard A P
authors.initials: GA
authors.lastname: Nieuwenhuijzen
authors.forename: Han J
authors.initials: HJ
authors.lastname: Bonenkamp
authors.forename: John Th M
authors.initials: JT
authors.lastname: Plukker
authors.forename: Ernst J Spillenaar
authors.initials: EJ
authors.lastname: Bilgen
authors.forename: Fibo J W
authors.initials: FJ
authors.lastname: Ten Kate
authors.forename: Ronald
authors.initials: R
authors.lastname: Boellaard
authors.forename: Jan
authors.initials: J
authors.lastname: Pruim
authors.forename: Gerrit W
authors.initials: GW
authors.lastname: Sloof
authors.forename: J Jan B
authors.initials: JJ
authors.lastname: van Lanschot